Researchers develop promising new cancer therapy



Researchers develop promising new cancer therapy

Immune checkpoint inhibitors such as Keytruda and Opdivo work by unleashing the immune system’s T cells to attack tumor cells. Their introduction a decade ago marked a major advance in cancer therapy, but only 10% to 30% of treated patients experience long-term improvement. New findings could now bolster the effectiveness of immune-checkpoint therapy.

Materials provided by Albert Einstein College of Medicine. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

31st March 2023

Form is (mal)function: Protein's shape lets bacteria disarm it

Read more
30th March 2023

Researchers discover a way to fight the aging process and cancer development

Read more
30th March 2023

Researchers identify cell type that could be key to preventing marrow transplant complication

Read more